Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Third Culture Capital (3CC) is a venture capital firm founded to support global-minded entrepreneurs in the healthcare sector. Established in the United States, 3CC focuses on early-stage investments that leverage unique life experiences to drive innovation. The firm emphasizes the importance of 'Third Culture' principles, which reflect a cross-cultural and cross-disciplinary approach to healthcare. This perspective is rooted in the belief that diverse backgrounds can lead to disruptive solutions in healthcare delivery.
Currently, 3CC manages a portfolio of 15 companies, with a check size range of $250,000 to $1 million. The firm operates primarily in the United States and has a keen interest in sectors such as healthcare, SaaS, fintech, and consumer markets. Notable milestones include their commitment to improving patient outcomes and enhancing care experiences through strategic investments in early-stage companies.
Third Culture Capital invests in early-stage companies that operate at the intersection of software and substrate (bio/data) within the healthcare sector. Their investment strategy encompasses a check size range of $250,000 to $1 million, targeting pre-seed, seed, and seed-plus stages. The firm is particularly interested in entrepreneurs who embody 'Third Culture' principles, which often include immigrants and first-generation Americans. This focus on cross-cultural entrepreneurs aligns with their belief that diverse experiences can lead to innovative solutions in healthcare.
3CC seeks companies that demonstrate potential to enhance patient outcomes, reduce costs, and improve the overall experience of care. Their investment criteria include a strong emphasis on technology-driven solutions that address significant challenges in healthcare delivery. The firm values founders who can articulate a clear vision for how their innovations will disrupt established markets and improve healthcare services.
Third Culture Capital's portfolio includes 15 companies that exemplify their investment focus on healthcare innovation. Notable portfolio companies include:
This diverse portfolio reflects 3CC's commitment to investing in companies that are poised to make significant impacts in healthcare through innovative technologies and solutions.
Julien L. Pham, MD, MPH - Founder & Managing Partner. Dr. Pham has a background in healthcare innovation and has led numerous investments in the sector.
Christine Hsieh, PhD - Operating Partner. Dr. Hsieh brings expertise in healthcare technology and operational strategy to the firm.
Denise Marks, CPA, MBA - Advisor. Marks provides financial oversight and strategic guidance to portfolio companies.
Ravi Thadhani, MD, MPH - Advisor. Dr. Thadhani specializes in healthcare delivery and policy, contributing valuable insights to the firm.
Guy Fish, MD, MBA - Special Advisor. Dr. Fish has extensive experience in healthcare management and innovation.
Maria V Lopez-Bresnahan, MD, MBA, FAAN - Advisor. Dr. Lopez-Bresnahan offers expertise in neurology and healthcare strategy, enhancing the firm's advisory capabilities.
To pitch Third Culture Capital, founders should use the contact form available on their website at thirdculturecapital.com. It is essential to include a detailed deck that outlines the business model, market opportunity, and how the solution addresses specific healthcare challenges. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
As of March 2026, Third Culture Capital continues to expand its portfolio, focusing on innovative healthcare startups. The firm has recently made investments in several companies that align with its mission to improve patient outcomes and enhance care experiences. Notable recent activities include the addition of new companies to their portfolio, reflecting their commitment to supporting early-stage healthcare innovation.
In addition to new investments, 3CC has been actively engaging with its existing portfolio companies, providing mentorship and resources to help them navigate the challenges of the healthcare market. The firm remains dedicated to its mission of empowering global-minded entrepreneurs who can disrupt established markets.
What are Third Culture Capital's investment criteria?
3CC focuses on early-stage companies in the healthcare sector that combine technology and biology. They seek entrepreneurs who embody 'Third Culture' principles and can demonstrate how their solutions will enhance patient outcomes and improve care delivery.
How can founders apply or pitch to Third Culture Capital?
Founders can pitch their ideas through the official website at thirdculturecapital.com. It is recommended to include a clear vision of how their innovation will disrupt the healthcare market.
What makes Third Culture Capital different from other investors?
3CC emphasizes the importance of unique life experiences and cross-cultural perspectives in their investment approach. They specifically target immigrant and first-generation American founders, believing that these backgrounds lead to innovative solutions in healthcare.
What is the geographic scope of Third Culture Capital's investments?
The firm primarily invests in companies based in the United States, focusing on early-stage healthcare innovations.
What is the typical check size for investments?
Third Culture Capital typically invests between $250,000 and $1 million in their portfolio companies, depending on the specific needs and potential of the business.
What kind of post-investment involvement does Third Culture Capital have?
3CC actively supports its portfolio companies by providing mentorship and resources that leverage the unique experiences of their founders, aiming to enhance patient outcomes and improve the overall experience of care.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.